RBC Capital lowered the firm’s price target on Surgery Partners (SGRY) to $35 from $49 and keeps an Outperform rating on the shares. The firm is updating its model after the company’s Q3 earnings miss earlier this month, though it remains confident in the management’s development strategy with sufficient liquidity and cash flow to fund future growth for Surgery Partners, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGRY:
- Surgery Partners post-earnings selloff overdone, says Macquarie
- Surgery Partners price target lowered to $31 from $32 at Barclays
- Surgery Partners price target lowered to $34 from $35 at Macquarie
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 25c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
